Fijal, Bonnie A <br/><br/>
CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.  [electronic resource] 

 -  Journal of clinical pharmacology  Oct 2015 
 - 1167-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1552-4604 
<br/><br/><label>Standard No.: </label>10.1002/jcph.530  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adrenergic Uptake Inhibitors--adverse effects<br/>Adult<br/>Atomoxetine Hydrochloride--adverse effects<br/>Attention Deficit Disorder with Hyperactivity--drug therapy<br/>Cytochrome P-450 CYP2D6--genetics<br/>Female<br/>Genotype<br/>Humans<br/>Male<br/>Phenotype<br/>Young Adult